Faricimab in RVO: 72-Week Results From the BALATON and
COMINO Phase III Studies
Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion
Effect of Bevacizumab vs Aflibercept on Visual Acuity (VA) Among Patients With Macular Edema Due to Central Retinal Vein Occlusion (CRVO): The SCORE2 Randomized Clinical Trial
Long-term Outcomes in Patients With Retinal Vein Occlusion (RVO) Treated With Ranibizumab: The RETAIN Study
Central retinal vein occlusion in young individuals: A comparison of risk factors and clinical outcomes
Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography
Impact of initial visual acuity (VA) on anti-VEGF treatment outcomes in patients with macular edema secondary to retinal vein occlusions (RVO) in routine clinical practice
Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion (RVO)
A 6-month, Subject-Masked, Randomized Controlled Study to Access Efficacy of Dexamethasone as an Adjunct to Bevacizumab Compared With Bevacizumab Alone in the Treatment of Patients With Macular Edema Due to Clinical or Branch Retinal Vein Occlusion
Fluctuations in Macular Thickness in Patients with Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor Agents
Long-Term Outcomes of Anti-VEGF Therapy in Patients With Macular Edema Secondary to Retinal Vein Occlusion
Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial
Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study